Back to results
US 10,941,210 B2Granted
Anti-PCSK9 antibodies
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsMark W. Sleeman, Joel H. Martin, Tammy T. Huang, Douglas Macdonald
Life of this patent
Estimating the term…
Abstract
An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.
Claims8
A nucleic acid molecule comprising:
- a first nucleotide sequence encoding a heavy chain variable region (HCVR) of an antibody that binds human proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein the HCVR comprises a heavy chain complementarity determining region (HCDR)1 comprising SEQ ID NO:76, an HCDR2 comprising SEQ ID NO:78, and an HCDR3 comprising SEQ ID NO:80;
- and
- a second nucleotide sequence encoding a light chain variable region (LCVR) of an antibody that binds human PCSK9, wherein the LCVR comprises a light chain complementarity determining region (LCDR)1 comprising SEQ ID NO:84, an LCDR2 comprising SEQ ID NO:86, and an LCDR3 comprising SEQ ID NO:88.
Dependencies are inferred from the claim text.